Pharmaceutical

Nxera Pharma and Antiverse to design antibodies targeting GPCRs

Nxera Pharma has entered a collaboration and licensing agreement with Antiverse to design antibodies for GPCRs.

Nov 7, 2024 - 06:00
Nxera Pharma and Antiverse to design antibodies targeting GPCRs
Nxera Pharma has entered a collaboration and licensing agreement with Antiverse to design antibodies for GPCRs.
Read the original article

Tags:

Previous Article

Trump triumphs but impact on healthcare industry remains unclear

Next Article

Ultra-processed food is causing a boom for obesity drug Ozempic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant

STAT+: FDA cites Dr. Reddy’s for quality control proble...

Nov 17, 2023

U.S. health officials lay out plans to cope with respiratory virus season

U.S. health officials lay out plans to cope with respir...

Aug 25, 2023

Northwestern and Case Western Reserve universities develop Huntington’s therapy

Northwestern and Case Western Reserve universities deve...

Nov 5, 2024